Intrinsic value of Nu Skin Enterprises Cl A - NUS

Previous Close

$55.48

  Intrinsic Value

$85.70

stock screener

  Rating & Target

str. buy

+54%

  Value-price divergence*

-60%

Previous close

$55.48

 
Intrinsic value

$85.70

 
Up/down potential

+54%

 
Rating

str. buy

 
Value-price divergence*

-60%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of NUS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -1.74
  5.70
  5.63
  5.57
  5.51
  5.46
  5.41
  5.37
  5.33
  5.30
  5.27
  5.24
  5.22
  5.20
  5.18
  5.16
  5.14
  5.13
  5.12
  5.11
  5.09
  5.09
  5.08
  5.07
  5.06
  5.06
  5.05
  5.05
  5.04
  5.04
  5.03
Revenue, $m
  2,208
  2,334
  2,465
  2,602
  2,746
  2,896
  3,053
  3,217
  3,388
  3,568
  3,756
  3,953
  4,159
  4,375
  4,602
  4,839
  5,088
  5,349
  5,623
  5,910
  6,211
  6,527
  6,858
  7,206
  7,571
  7,953
  8,355
  8,777
  9,219
  9,683
  10,171
Variable operating expenses, $m
 
  1,495
  1,579
  1,666
  1,757
  1,853
  1,952
  2,057
  2,166
  2,280
  2,399
  2,513
  2,644
  2,782
  2,926
  3,077
  3,235
  3,401
  3,575
  3,758
  3,949
  4,150
  4,360
  4,581
  4,813
  5,057
  5,312
  5,580
  5,861
  6,157
  6,466
Fixed operating expenses, $m
 
  590
  605
  620
  636
  652
  668
  685
  702
  719
  737
  756
  775
  794
  814
  834
  855
  876
  898
  921
  944
  967
  992
  1,016
  1,042
  1,068
  1,095
  1,122
  1,150
  1,179
  1,208
Total operating expenses, $m
  1,977
  2,085
  2,184
  2,286
  2,393
  2,505
  2,620
  2,742
  2,868
  2,999
  3,136
  3,269
  3,419
  3,576
  3,740
  3,911
  4,090
  4,277
  4,473
  4,679
  4,893
  5,117
  5,352
  5,597
  5,855
  6,125
  6,407
  6,702
  7,011
  7,336
  7,674
Operating income, $m
  231
  248
  281
  316
  353
  391
  432
  475
  521
  569
  619
  684
  740
  799
  862
  928
  998
  1,072
  1,150
  1,232
  1,318
  1,410
  1,506
  1,608
  1,715
  1,829
  1,948
  2,075
  2,208
  2,348
  2,496
EBITDA, $m
  303
  314
  350
  388
  428
  470
  515
  562
  611
  663
  718
  776
  837
  901
  969
  1,041
  1,117
  1,196
  1,281
  1,369
  1,463
  1,562
  1,666
  1,776
  1,892
  2,014
  2,143
  2,279
  2,422
  2,574
  2,733
Interest expense (income), $m
  12
  12
  14
  15
  17
  18
  20
  22
  24
  26
  28
  30
  33
  35
  38
  40
  43
  46
  49
  53
  56
  59
  63
  67
  71
  76
  80
  85
  90
  95
  101
Earnings before tax, $m
  213
  236
  268
  301
  336
  373
  412
  453
  497
  543
  591
  653
  707
  764
  824
  888
  955
  1,026
  1,100
  1,179
  1,262
  1,350
  1,443
  1,541
  1,644
  1,753
  1,868
  1,990
  2,118
  2,253
  2,395
Tax expense, $m
  70
  64
  72
  81
  91
  101
  111
  122
  134
  146
  160
  176
  191
  206
  223
  240
  258
  277
  297
  318
  341
  365
  390
  416
  444
  473
  504
  537
  572
  608
  647
Net income, $m
  143
  172
  195
  220
  245
  272
  301
  331
  363
  396
  431
  477
  516
  558
  602
  648
  697
  749
  803
  861
  922
  986
  1,053
  1,125
  1,200
  1,280
  1,364
  1,452
  1,546
  1,645
  1,749

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  369
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,474
  1,168
  1,234
  1,303
  1,374
  1,449
  1,528
  1,610
  1,696
  1,786
  1,880
  1,978
  2,082
  2,190
  2,303
  2,422
  2,547
  2,677
  2,814
  2,958
  3,109
  3,267
  3,433
  3,607
  3,789
  3,981
  4,182
  4,393
  4,614
  4,847
  5,090
Adjusted assets (=assets-cash), $m
  1,105
  1,168
  1,234
  1,303
  1,374
  1,449
  1,528
  1,610
  1,696
  1,786
  1,880
  1,978
  2,082
  2,190
  2,303
  2,422
  2,547
  2,677
  2,814
  2,958
  3,109
  3,267
  3,433
  3,607
  3,789
  3,981
  4,182
  4,393
  4,614
  4,847
  5,090
Revenue / Adjusted assets
  1.998
  1.998
  1.998
  1.997
  1.999
  1.999
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
  1.998
Average production assets, $m
  515
  544
  574
  606
  640
  675
  711
  749
  789
  831
  875
  921
  969
  1,019
  1,072
  1,128
  1,186
  1,246
  1,310
  1,377
  1,447
  1,521
  1,598
  1,679
  1,764
  1,853
  1,947
  2,045
  2,148
  2,256
  2,370
Working capital, $m
  315
  30
  32
  34
  36
  38
  40
  42
  44
  46
  49
  51
  54
  57
  60
  63
  66
  70
  73
  77
  81
  85
  89
  94
  98
  103
  109
  114
  120
  126
  132
Total debt, $m
  417
  376
  419
  464
  511
  561
  612
  666
  723
  782
  844
  909
  977
  1,048
  1,123
  1,201
  1,283
  1,369
  1,459
  1,553
  1,652
  1,757
  1,866
  1,980
  2,100
  2,226
  2,359
  2,497
  2,643
  2,796
  2,957
Total liabilities, $m
  810
  769
  812
  857
  904
  954
  1,005
  1,059
  1,116
  1,175
  1,237
  1,302
  1,370
  1,441
  1,516
  1,594
  1,676
  1,762
  1,852
  1,946
  2,045
  2,150
  2,259
  2,373
  2,493
  2,619
  2,752
  2,890
  3,036
  3,189
  3,350
Total equity, $m
  664
  399
  422
  445
  470
  496
  523
  551
  580
  611
  643
  677
  712
  749
  788
  828
  871
  916
  962
  1,012
  1,063
  1,117
  1,174
  1,233
  1,296
  1,361
  1,430
  1,502
  1,578
  1,658
  1,741
Total liabilities and equity, $m
  1,474
  1,168
  1,234
  1,302
  1,374
  1,450
  1,528
  1,610
  1,696
  1,786
  1,880
  1,979
  2,082
  2,190
  2,304
  2,422
  2,547
  2,678
  2,814
  2,958
  3,108
  3,267
  3,433
  3,606
  3,789
  3,980
  4,182
  4,392
  4,614
  4,847
  5,091
Debt-to-equity ratio
  0.628
  0.940
  0.990
  1.040
  1.090
  1.130
  1.170
  1.210
  1.250
  1.280
  1.310
  1.340
  1.370
  1.400
  1.430
  1.450
  1.470
  1.490
  1.520
  1.540
  1.550
  1.570
  1.590
  1.610
  1.620
  1.640
  1.650
  1.660
  1.670
  1.690
  1.700
Adjusted equity ratio
  0.267
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342
  0.342

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  143
  172
  195
  220
  245
  272
  301
  331
  363
  396
  431
  477
  516
  558
  602
  648
  697
  749
  803
  861
  922
  986
  1,053
  1,125
  1,200
  1,280
  1,364
  1,452
  1,546
  1,645
  1,749
Depreciation, amort., depletion, $m
  72
  66
  69
  72
  75
  79
  83
  86
  90
  95
  99
  92
  97
  102
  107
  113
  119
  125
  131
  138
  145
  152
  160
  168
  176
  185
  195
  204
  215
  226
  237
Funds from operations, $m
  303
  238
  264
  292
  321
  351
  383
  417
  453
  491
  530
  569
  613
  660
  709
  761
  816
  873
  934
  998
  1,066
  1,138
  1,213
  1,293
  1,377
  1,465
  1,559
  1,657
  1,761
  1,870
  1,986
Change in working capital, $m
  28
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
Cash from operations, $m
  275
  237
  263
  290
  319
  349
  381
  415
  451
  488
  528
  567
  611
  657
  706
  758
  812
  870
  931
  995
  1,062
  1,134
  1,209
  1,288
  1,372
  1,460
  1,553
  1,651
  1,755
  1,864
  1,979
Maintenance CAPEX, $m
  0
  -51
  -54
  -57
  -61
  -64
  -67
  -71
  -75
  -79
  -83
  -88
  -92
  -97
  -102
  -107
  -113
  -119
  -125
  -131
  -138
  -145
  -152
  -160
  -168
  -176
  -185
  -195
  -204
  -215
  -226
New CAPEX, $m
  -50
  -29
  -31
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -48
  -50
  -53
  -55
  -58
  -61
  -64
  -67
  -70
  -74
  -77
  -81
  -85
  -89
  -94
  -98
  -103
  -108
  -114
Cash from investing activities, $m
  -58
  -80
  -85
  -89
  -94
  -99
  -104
  -109
  -115
  -121
  -127
  -134
  -140
  -147
  -155
  -162
  -171
  -180
  -189
  -198
  -208
  -219
  -229
  -241
  -253
  -265
  -279
  -293
  -307
  -323
  -340
Free cash flow, $m
  217
  156
  178
  201
  225
  250
  277
  306
  336
  368
  401
  433
  470
  510
  551
  595
  642
  691
  742
  797
  854
  915
  980
  1,047
  1,119
  1,195
  1,274
  1,359
  1,447
  1,541
  1,640
Issuance/(repayment) of debt, $m
  178
  42
  43
  45
  47
  49
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
  95
  99
  104
  109
  114
  120
  126
  132
  139
  146
  153
  161
Issuance/(repurchase) of shares, $m
  -233
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -57
  42
  43
  45
  47
  49
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
  95
  99
  104
  109
  114
  120
  126
  132
  139
  146
  153
  161
Total cash flow (excl. dividends), $m
  146
  197
  221
  246
  272
  300
  329
  360
  392
  427
  463
  498
  538
  581
  626
  673
  724
  777
  832
  891
  954
  1,019
  1,089
  1,162
  1,239
  1,321
  1,407
  1,497
  1,593
  1,694
  1,801
Retained Cash Flow (-), $m
  162
  -21
  -22
  -23
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -52
  -54
  -57
  -60
  -62
  -66
  -69
  -72
  -76
  -79
  -83
Prev. year cash balance distribution, $m
 
  286
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  462
  198
  222
  248
  274
  302
  332
  363
  396
  431
  464
  503
  544
  587
  633
  681
  732
  786
  842
  902
  965
  1,032
  1,102
  1,177
  1,255
  1,338
  1,425
  1,517
  1,615
  1,717
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  443
  182
  194
  204
  213
  219
  224
  227
  227
  226
  221
  215
  207
  197
  186
  173
  159
  145
  130
  115
  100
  86
  72
  60
  49
  39
  31
  23
  18
  13
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin-care systems and treatment products, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care system, and ageLOC Tru Face Essence Ultra anti-aging skin care serum, as well as other cosmetic, personal care, and hair care products. The company also offers LifePak and ageLOC R2 nutritional supplements, and ageLOC TR90 weight management and body shaping systems. In addition, it is involved in the research and product development of aging, such as the influence of certain ingredients on gene expression. The company sells its products directly, as well as through its retail stores and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

FINANCIAL RATIOS  of  Nu Skin Enterprises Cl A (NUS)

Valuation Ratios
P/E Ratio 20.4
Price to Sales 1.3
Price to Book 4.4
Price to Tangible Book
Price to Cash Flow 10.6
Price to Free Cash Flow 13
Growth Rates
Sales Growth Rate -1.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -12.3%
Cap. Spend. - 3 Yr. Gr. Rate -23%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 50.3%
Total Debt to Equity 62.8%
Interest Coverage 19
Management Effectiveness
Return On Assets 10.1%
Ret/ On Assets - 3 Yr. Avg. 10%
Return On Total Capital 13.3%
Ret/ On T. Cap. - 3 Yr. Avg. 14%
Return On Equity 19.2%
Return On Equity - 3 Yr. Avg. 18.4%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 77.3%
Gross Margin - 3 Yr. Avg. 79%
EBITDA Margin 13.5%
EBITDA Margin - 3 Yr. Avg. 13.4%
Operating Margin 10.5%
Oper. Margin - 3 Yr. Avg. 11.7%
Pre-Tax Margin 9.6%
Pre-Tax Margin - 3 Yr. Avg. 10.2%
Net Profit Margin 6.5%
Net Profit Margin - 3 Yr. Avg. 6.6%
Effective Tax Rate 32.9%
Eff/ Tax Rate - 3 Yr. Avg. 35.6%
Payout Ratio 54.5%

NUS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NUS stock intrinsic value calculation we used $2208 million for the last fiscal year's total revenue generated by Nu Skin Enterprises Cl A. The default revenue input number comes from 2016 income statement of Nu Skin Enterprises Cl A. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NUS stock valuation model: a) initial revenue growth rate of 5.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NUS is calculated based on our internal credit rating of Nu Skin Enterprises Cl A, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Nu Skin Enterprises Cl A.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NUS stock the variable cost ratio is equal to 64.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $576 million in the base year in the intrinsic value calculation for NUS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.6% for Nu Skin Enterprises Cl A.

Corporate tax rate of 27% is the nominal tax rate for Nu Skin Enterprises Cl A. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NUS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NUS are equal to 23.3%.

Life of production assets of 10 years is the average useful life of capital assets used in Nu Skin Enterprises Cl A operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NUS is equal to 1.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $664 million for Nu Skin Enterprises Cl A - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 53.934 million for Nu Skin Enterprises Cl A is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Nu Skin Enterprises Cl A at the current share price and the inputted number of shares is $3.0 billion.

RELATED COMPANIES Price Int.Val. Rating
HLF Herbalife 61.95 67.76  hold
AVP Avon Products 2.62 0.28  str.sell
NHTC Natural Health 18.55 75.00  str.buy
USNA USANA Health S 56.55 89.06  buy
NATR Nature's S 9.95 8.75  sell
RELV Reliv Internat 7.50 2.00  str.sell
PG Procter&Gamble 92.47 51.93  sell
ILMN Illumina 189.32 71.07  str.sell
LXRX Lexicon Pharma 14.00 32.69  str.buy
LFVN Lifevantage 2.99 12.60  str.buy

COMPANY NEWS

▶ Top Ranked Growth Stocks to Buy for August 16th   [Aug-16-17 10:23AM  Zacks]
▶ Nu Skin beats 2Q profit forecasts   [Aug-02-17 11:13PM  Associated Press]
▶ The highest-paid CEOs by state   [06:35AM  Associated Press]
▶ Beauty Companies Eye Millennial Customer Base   [May-10-17 05:11PM  Investopedia]
▶ Nu Skin beats 1Q profit forecasts   [May-03-17 07:05PM  Associated Press]
▶ Top 4 Cosmetics Stocks of 2017   [Apr-13-17 11:44AM  Investopedia]
▶ Nu Skin Enterprises To Report First-Quarter 2017 Results   [Apr-10-17 04:15PM  PR Newswire]
▶ Take a Fresh Look at Nu Skin Enterprises   [Mar-09-17 03:06PM  TheStreet.com]
▶ Unusual Activity: GLD & NUS   [Feb-24-17 12:55PM  CNBC Videos]
▶ Why Nu Skin Enterprises Stock Dropped Today   [01:30PM  at Motley Fool]
▶ Why Nu Skin Has Tumbled 13%   [12:24PM  at Barrons.com]
▶ Nu Skin shares skid as revenue shrinks   [04:39PM  at MarketWatch]
▶ This Stock Could Be the Next Dividend Aristocrat   [Feb-12-17 09:34PM  at Motley Fool]
▶ Nu Skin Enterprises To Present At ICR 2017 Conference   [Jan-05-17 05:02PM  PR Newswire]
▶ [$$] Avon's Promising Makeover   [Dec-10-16 12:01AM  at Barrons.com]
Stock chart of NUS Financial statements of NUS
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.